| abstract |
The present invention is related to the treatment and prevention of cancer including particularly gastrointestinal cancer. More specifically, the present invention describes the use of naltrexone, naloxone and the pentapeptide growth factor [Met<5>]-enkephalin to inhibit and arrest the growth of cancer. Such efficiency has been discovered to be a consequence of the functional manipulation of the zeta (zeta) opioid receptor through endogenous [Met<5>]-enkephalin. This receptor has been determined to be present in growing cancers such as pancreatic and colon cancer, for example. |